Literature DB >> 17881751

Long-term outcomes after repeat doses of antenatal corticosteroids.

Ronald J Wapner1, Yoram Sorokin, Lisa Mele, Francee Johnson, Donald J Dudley, Catherine Y Spong, Alan M Peaceman, Kenneth J Leveno, Fergal Malone, Steve N Caritis, Brian Mercer, Margaret Harper, Dwight J Rouse, John M Thorp, Susan Ramin, Marshall W Carpenter, Steven G Gabbe.   

Abstract

BACKGROUND: Previous trials have shown that repeat courses of antenatal corticosteroids improve some neonatal outcomes in preterm infants but reduce birth weight and increase the risk of intrauterine growth restriction. We report long-term follow-up results of children enrolled in a randomized trial comparing single and repeat courses of antenatal corticosteroids.
METHODS: Women at 23 through 31 weeks of gestation who remained pregnant 7 days after an initial course of corticosteroids were randomly assigned to weekly courses of betamethasone, consisting of 12 mg given intramuscularly and repeated once at 24 hours, or an identical-appearing placebo. We studied the children who were born after these treatments when they were between 2 and 3 years of corrected age. Prespecified outcomes included scores on the Bayley Scales of Infant Development, anthropometric measurements, and the presence of cerebral palsy.
RESULTS: A total of 556 infants were available for follow-up; 486 children (87.4%) underwent physical examination and 465 (83.6%) underwent Bayley testing at a mean (+/-SD) corrected age of 29.3+/-4.6 months. There were no significant differences in Bayley results or anthropometric measurements. Six children (2.9% of pregnancies) in the repeat-corticosteroid group had cerebral palsy as compared with one child (0.5% of pregnancies) in the placebo group (relative risk, 5.7; 95% confidence interval, 0.7 to 46.7; P=0.12).
CONCLUSIONS: Children who had been exposed to repeat as compared with single courses of antenatal corticosteroids did not differ significantly in physical or neurocognitive measures. Although the difference was not statistically significant, the higher rate of cerebral palsy among children who had been exposed to repeat doses of corticosteroids is of concern and warrants further study. (ClinicalTrials.gov number, NCT00015002 [ClinicalTrials.gov].). Copyright 2007 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881751     DOI: 10.1056/NEJMoa071453

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  76 in total

1.  Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation.

Authors:  Waldemar A Carlo; Scott A McDonald; Avroy A Fanaroff; Betty R Vohr; Barbara J Stoll; Richard A Ehrenkranz; William W Andrews; Dennis Wallace; Abhik Das; Edward F Bell; Michele C Walsh; Abbot R Laptook; Seetha Shankaran; Brenda B Poindexter; Ellen C Hale; Nancy S Newman; Alexis S Davis; Kurt Schibler; Kathleen A Kennedy; Pablo J Sánchez; Krisa P Van Meurs; Ronald N Goldberg; Kristi L Watterberg; Roger G Faix; Ivan D Frantz; Rosemary D Higgins
Journal:  JAMA       Date:  2011-12-07       Impact factor: 56.272

2.  Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype.

Authors:  Nghia C Truong; Afshan Abbasi; Reiko Sakurai; W N Paul Lee; John S Torday; Virender K Rehan
Journal:  Neonatology       Date:  2011-11-10       Impact factor: 4.035

3.  The clinical significance of a positive Amnisure test in women with preterm labor and intact membranes.

Authors:  Seung Mi Lee; Roberto Romero; Jeong Woo Park; Sun Min Kim; Chan-Wook Park; Steven J Korzeniewski; Tinnakorn Chaiworapongsa; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2012-04-25

4.  Antenatal glucocorticoid treatment alters Na+ uptake in renal proximal tubule cells from adult offspring in a sex-specific manner.

Authors:  Yixin Su; Jianli Bi; Victor M Pulgar; Jorge Figueroa; Mark Chappell; James C Rose
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-01

5.  The timing of prenatal exposure to maternal cortisol and psychosocial stress is associated with human infant cognitive development.

Authors:  Elysia P Davis; Curt A Sandman
Journal:  Child Dev       Date:  2010 Jan-Feb

6.  Caveolin-1 regulates genomic action of the glucocorticoid receptor in neural stem cells.

Authors:  Melanie E Peffer; Uma R Chandran; Soumya Luthra; Daniela Volonte; Ferruccio Galbiati; Michael J Garabedian; A Paula Monaghan; Donald B DeFranco
Journal:  Mol Cell Biol       Date:  2014-07       Impact factor: 4.272

Review 7.  Steroids and injury to the developing brain: net harm or net benefit?

Authors:  Shadi N Malaeb; Barbara S Stonestreet
Journal:  Clin Perinatol       Date:  2014-03       Impact factor: 3.430

Review 8.  Minireview: the impact of antenatal therapeutic synthetic glucocorticoids on the developing fetal brain.

Authors:  Melanie E Peffer; Janie Y Zhang; Leah Umfrey; Anthony C Rudine; A Paula Monaghan; Donald B DeFranco
Journal:  Mol Endocrinol       Date:  2015-03-12

9.  Pulmonary function and outcomes in infants randomized to a rescue course of antenatal steroids.

Authors:  Cindy McEvoy; Diane Schilling; Patricia Spitale; Jean O'Malley; Susan Bowling; Manuel Durand
Journal:  Pediatr Pulmonol       Date:  2017-04-24

10.  Antenatal betamethasone depresses maternal and fetal aldosterone levels.

Authors:  Julie M Kessel; Jackie M Cale; Erin Verbrick; C Richard Parker; David P Carlton; Ian M Bird
Journal:  Reprod Sci       Date:  2009-01       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.